Antigenic Drift and Immunity Gap Explain Reduction in Protective Responses Against Influenza A(H1N1)pdm09 and A(H3N2) Viruses During the COVID-19 Pandemic: a Cross-sectional Study of Human Sera Collected in 2019, 2021, 2022, and 2023

Overview

Journal Virol J

Publisher Biomed Central

Specialty Microbiology

Date 2024 Mar 6

PMID 38448981

Authors

Even Fossum

Andreas Rohringer

Torstein Aune

Kjersti Margrethe Rydland

Karoline Bragstad

Olav Hungnes

Affiliations

Soon will be listed here.

Abstract

Background: Non-pharmaceutical interventions implemented during the COVID-19 pandemic resulted in a marked reduction in influenza infections globally. The absence of influenza has raised concerns of waning immunity, and potentially more severe influenza seasons after the pandemic.

Methods: To evaluate immunity towards influenza post-COVID-19 pandemic we have assessed influenza A epidemics in Norway from October 2016 to June 2023 and measured antibodies against circulating strains of influenza A(H1N1)pdm09 and A(H3N2) in different age groups by hemagglutination inhibition (HAI) assays in a total of 3364 serum samples collected in 2019, 2021, 2022 and 2023.

Results: Influenza epidemics in Norway from October 2016 until June 2023 were predominately influenza As, with a mixture of A(H1N1)pdm09 and A(H3N2) subtype predominance. We did not observe higher numbers of infections during the influenza epidemics following the COVID-19 pandemic than in pre-COVID-19 seasons. Frequencies of protective HAI titers against A(H1N1)pdm09 and A(H3N2) viruses were reduced in sera collected in 2021 and 2022, compared to sera collected in 2019. The reduction could, however, largely be explained by antigenic drift of new virus strains, as protective HAI titers remained stable against the same strain from one season to the next. However, we observed the development of an immunity gap in the youngest children during the pandemic which resulted in a prominent reduction in HAI titers against A(H1N1)pdm09 in 2021 and 2022. The immunity gap was partially closed in sera collected in 2023 following the A(H1N1)pdm09-dominated influenza seasons of 2022/2023. During the 2022/2023 epidemic, drift variants of A(H1N1)pdm09 belonging to the 5a.2a.1 clade emerged, and pre-season HAI titers were significantly lower against this clade compared to the ancestral 5a.2 clade.

Conclusion: The observed reduction in protective antibodies against A(H1N1)pdm09 and A(H3N2) viruses post COVID-19 is best explained by antigenic drift of emerging viruses, and not waning of antibody responses in the general population. However, the absence of influenza during the pandemic resulted in an immunity gap in the youngest children. While this immunity gap was partially closed following the 2022/2023 influenza season, children with elevated risk of severe infection should be prioritized for vaccination.

Citing Articles

Resurgence of common respiratory viruses and mycoplasma pneumoniae after ending the zero-COVID policy in Shanghai.

Liu P, Xu M, Lu L, Zhu X, Jia R, Dong N Sci Rep. 2025; 15(1):1765.

PMID: 39800785 PMC: 11725580. DOI: 10.1038/s41598-025-85852-z.

Seasonal Shifts in Influenza, Respiratory Syncytial Virus, and Other Respiratory Viruses After the COVID-19 Pandemic: An Eight-Year Retrospective Study in Jalisco, Mexico.

Quintero-Salgado E, Briseno-Ramirez J, Vega-Cornejo G, Damian-Negrete R, Rosales-Chavez G, De Arcos-Jimenez J Viruses. 2025; 16(12.

PMID: 39772198 PMC: 11680140. DOI: 10.3390/v16121892.

Development and validation of a nomogram for predicting occurrence of severe case in children hospitalized with influenza A (H1N1) infection during the post-COVID-19 era.

Liu H, Hu X, Liu C, Guo Z, Lu R, Xiang M Heliyon. 2024; 10(15):e35571.

PMID: 39170375 PMC: 11336715. DOI: 10.1016/j.heliyon.2024.e35571.

Correction: antigenic drift and immunity gap explain reduction in protective responses against influenza A(H1N1)pdm09 and A(H3N2) viruses during the COVID-19 pandemic: a cross-sectional study of human sera collected in 2019, 2021, 2022, and 2023.

Fossum E, Rohringer A, Aune T, Rydland K, Bragstad K, Hungnes O Virol J. 2024; 21(1):66.

PMID: 38500208 PMC: 10946110. DOI: 10.1186/s12985-024-02341-x.

References

Emborg H, Carnahan A, Bragstad K, Trebbien R, Brytting M, Hungnes O . Abrupt termination of the 2019/20 influenza season following preventive measures against COVID-19 in Denmark, Norway and Sweden. Euro Surveill. 2021; 26(22). PMC: 8176675. DOI: 10.2807/1560-7917.ES.2021.26.22.2001160. View

Saunes I, Vrangbaek K, Byrkjeflot H, Jervelund S, Birk H, Tynkkynen L . Nordic responses to Covid-19: Governance and policy measures in the early phases of the pandemic. Health Policy. 2021; 126(5):418-426. PMC: 8418563. DOI: 10.1016/j.healthpol.2021.08.011. View

Agha R, Avner J . Delayed Seasonal RSV Surge Observed During the COVID-19 Pandemic. Pediatrics. 2021; 148(3). DOI: 10.1542/peds.2021-052089. View

Opek M, Yeshayahu Y, Glatman-Freedman A, Kaufman Z, Sorek N, Brosh-Nissimov T . Delayed respiratory syncytial virus epidemic in children after relaxation of COVID-19 physical distancing measures, Ashdod, Israel, 2021. Euro Surveill. 2021; 26(29). PMC: 8299746. DOI: 10.2807/1560-7917.ES.2021.26.29.2100706. View

Foley D, Yeoh D, Minney-Smith C, Martin A, Mace A, Sikazwe C . The Interseasonal Resurgence of Respiratory Syncytial Virus in Australian Children Following the Reduction of Coronavirus Disease 2019-Related Public Health Measures. Clin Infect Dis. 2021; 73(9):e2829-e2830. PMC: 7929151. DOI: 10.1093/cid/ciaa1906. View

Chen B, Zhu Z, Li Q, He D . Resurgence of different influenza types in China and the US in 2021. Math Biosci Eng. 2023; 20(4):6327-6333. DOI: 10.3934/mbe.2023273. View

Sominina A, Danilenko D, Komissarov A, Karpova L, Pisareva M, Fadeev A . Resurgence of Influenza Circulation in the Russian Federation during the Delta and Omicron COVID-19 Era. Viruses. 2022; 14(9). PMC: 9506591. DOI: 10.3390/v14091909. View

Krammer F . The human antibody response to influenza A virus infection and vaccination. Nat Rev Immunol. 2019; 19(6):383-397. DOI: 10.1038/s41577-019-0143-6. View

Fisman D, Savage R, Gubbay J, Achonu C, Akwar H, Farrell D . Older age and a reduced likelihood of 2009 H1N1 virus infection. N Engl J Med. 2009; 361(20):2000-1. DOI: 10.1056/NEJMc0907256. View

10.

Hancock K, Veguilla V, Lu X, Zhong W, Butler E, Sun H . Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009; 361(20):1945-52. DOI: 10.1056/NEJMoa0906453. View

11.

Waalen K, Kilander A, Dudman S, Krogh G, Aune T, Hungnes O . High prevalence of antibodies to the 2009 pandemic influenza A(H1N1) virus in the Norwegian population following a major epidemic and a large vaccination campaign in autumn 2009. Euro Surveill. 2010; 15(31). View

12.

Yu X, Tsibane T, McGraw P, House F, Keefer C, Hicar M . Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature. 2008; 455(7212):532-6. PMC: 2848880. DOI: 10.1038/nature07231. View

13.

Ray G, Lewis N, Klein N, Daley M, Wang S, Kulldorff M . Intraseason Waning of Influenza Vaccine Effectiveness. Clin Infect Dis. 2018; 68(10):1623-1630. PMC: 7182205. DOI: 10.1093/cid/ciy770. View

14.

Ferdinands J, Fry A, Reynolds S, Petrie J, Flannery B, Jackson M . Intraseason waning of influenza vaccine protection: Evidence from the US Influenza Vaccine Effectiveness Network, 2011-12 through 2014-15. Clin Infect Dis. 2017; 64(5):544-550. DOI: 10.1093/cid/ciw816. View

15.

Young B, Zhao X, Cook A, Parry C, Wilder-Smith A, I-Cheng M . Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis. Vaccine. 2016; 35(2):212-221. DOI: 10.1016/j.vaccine.2016.11.013. View

16.

Mordant F, Price O, Rudraraju R, Slavin M, Marshall C, Worth L . Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post-vaccination but persist for at least 6 months. Influenza Other Respir Viruses. 2022; 17(1):e13072. PMC: 9835415. DOI: 10.1111/irv.13072. View

17.

Haaheim L . Surveillance of the antibody status to current influenza strains in the Norwegian population. 1: Method of serum sampling and evaluation of the A/USSR/77 (H1N1) impact in various age groups in 1978. NIPH Ann. 1979; 2(2):45-54. View

18.

Haaheim L . Surveillance of the antibody status to current influenza strains in the Norwegian population. 2: Antibodies to the A/USSR/90/77 (H1N1) virus in various age groups after the second epidemic wave. NIPH Ann. 1980; 3(1):49-56. View

19.

Hobson D, CURRY R, Beare A . The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972; 70(4):767-77. PMC: 2130285. DOI: 10.1017/s0022172400022610. View

20.

POTTER C, Oxford J . Determinants of immunity to influenza infection in man. Br Med Bull. 1979; 35(1):69-75. DOI: 10.1093/oxfordjournals.bmb.a071545. View